Sophie E Lehar

US Patent:

6586204, Jul 1, 2003

Filed:

Sep 11, 1998

Appl. No.:

09/151771

Inventors:

Sophie M. Lehar - Berlin MA
Braydon C. Guild - Concord MA

Assignee:

Apoptosis Technology, Inc. - Cambridge MA

International Classification:

C12P 1563

US Classification:

435 691, 435375, 435455, 530350, 536 231

Abstract:

Disclosed is the isolation and characterization of EI24, a novel gene whose 2. 4 kb mRNA is induced following etoposide treatment. Induction of EI24 mRNA by etoposide required expression of wild-type p53. Overexpression of functional p53 was sufficient to induce expression of the EI24 mRNA. The EI24 mRNA was also induced in a p53-dependent manner by ionizing irradiation of primary murine thymocytes. The invention is thus directed to an isolated EI24 protein, nucleotide sequences coding for and regulating expression of the protein, antibodies directed against the protein, and recombinant vectors and host cells containing the genetic sequences coding for and regulating the expression of the protein sequence. The invention is also directed to genomic DNA, cDNA, and RNA encoding the EI24 protein sequence and to corresponding antisense RNA sequences. Antibodies can be used to detect EI24 in biological specimens, including, for example, human tissue samples.

US Patent:

7078175, Jul 18, 2006

Filed:

Mar 12, 2003

Appl. No.:

10/385450

Inventors:

Sophie M. Lehar - Berlin MA, US
Braydon C. Guild - Concord MA, US

Assignee:

Immunogen, Inc. - Cambridge MA

International Classification:

G01N 33/53
C07K 16/00
C12P 21/08
C12N 9/96

US Classification:

435 71, 5303871, 5303872, 5303873, 5303881, 5303891, 5303911, 5303913, 435188

Abstract:

Disclosed is the isolation and characterization of EI24, a gene whose 2. 4 kb mRNA is induced following etoposide treatment. Induction of EI24 mRNA by etoposide required expression of wild-type p53. Overexpression of functional p53 was sufficient to induce expression of the EI24 mRNA. The EI24 mRNA was also induced in a p53-dependent manner by ionizing irradiation of primary murine thymocytes. The invention is thus directed to an isolated EI24 protein, nucleotide sequences coding for and regulating expression of the protein, antibodies directed against the protein, and recombinant vectors and host cells containing the genetic sequences coding for and regulating the expression of the protein sequence. Antibodies can be used to detect EI24 in biological specimens, including, for example, human tissue samples.

US Patent:

20020164697, Nov 7, 2002

Filed:

Nov 20, 2001

Appl. No.:

09/989545

Inventors:

Anthony Coyle - Boston MA, US
Stephen Manning - Arlington MA, US
Sophie Lehar - Seattle WA, US
Jose-Carlos Gutierrez-Ramos - Swampscott MA, US

Assignee:

Millennium Pharmaceuticals, Inc.

International Classification:

C07H021/04
C12N009/00
C12P021/02
C12N005/06

US Classification:

435/069100, 435/183000, 435/320100, 435/325000, 536/023200

Abstract:

Novel Th2-specific polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Th2-specific proteins, the invention further provides isolated Th2-specific fusion proteins, antigenic peptides, and anti-Th2-specific antibodies. The invention also provides Th2-specific nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Th2-specific gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

US Patent:

20050202013, Sep 15, 2005

Filed:

May 3, 2005

Appl. No.:

11/120777

Inventors:

Anthony Coyle - Boston MA, US
Stephen Manning - Arlington MA, US
Sophie Lehar - Seattle WA, US
Jose-Carlos Gutierrez-Ramos - Swampscott MA, US

International Classification:

G01N033/567
C07H021/04
A61K039/395
C12N015/09
C07K014/74
C07K016/28

US Classification:

424144100, 435069100, 435320100, 435372000, 530350000, 530388220, 536023500, 435007210

Abstract:

Novel Th2-specific polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Th2-specific proteins, the invention further provides isolated Th2-specific fusion proteins, antigenic peptides, and anti-Th2-specific antibodies. The invention also provides Th2-specific nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Th2-specific gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

US Patent:

20090081642, Mar 26, 2009

Filed:

Apr 21, 2006

Appl. No.:

11/408067

Inventors:

Sophie M. Lehar - Berlin MA, US
Braydon C. Guild - Concord MA, US

Assignee:

Apoptosis Technology, Inc. - Cambridge MA

International Classification:

C12Q 1/68
C12N 15/11
C12N 15/00
C12P 21/04
C12N 5/06
C07H 21/04

US Classification:

435 6, 536 235, 4353201, 435 691, 435325, 536 2431

Abstract:

Disclosed is the isolation and characterization of EI24, a novel gene whose 2.4 kb mRNA is induced following etoposide treatment. Induction of EI24 mRNA by etoposide required expression of wild-type p53. Overexpression of functional p53 was sufficient to induce expression of the EI24 mRNA. The EI24 mRNA was also induced in a p53-dependent manner by ionizing irradiation of primary murine thymocytes. The invention is thus directed to an isolated EI24 protein, nucleotide sequences coding for and regulating expression of the protein, antibodies directed against the protein, and recombinant vectors and host cells containing the genetic sequences coding for and regulating the expression of the protein sequence. The invention is also directed to genomic DNA, cDNA, and RNA encoding the EI24 protein sequence and to corresponding antisense RNA sequences. Antibodies can be used to detect EI24 in biological specimens, including, for example, human tissue samples. The present invention is further directed to methods of treating degenerative disorders characterized in inappropriate cell proliferation or inappropriate cell death. The present invention is further directed to methods for diagnosing degenerative disorders characterized in inappropriate cell proliferation or inappropriate cell death, as well as methods for monitoring the progress of such degenerative disorders.

US Patent:

58436596, Dec 1, 1998

Filed:

Mar 21, 1996

Appl. No.:

8/619362

Inventors:

Sophie M. Lehar - Berlin MA
Braydon C. Guild - Concord MA

Assignee:

Apoptosis Technology, Inc. - Cambridge MA

International Classification:

C12Q 168
C12P 2100
C12N 510
C07H 2104

US Classification:

435 6

Abstract:

Disclosed is the isolation and characterization of EI24, a novel gene whose 2. 4 kb mRNA is induced following etoposide treatment. Induction of EI24 mRNA by etoposide required expression of wild-type p53. Overexpression of functional p53 was sufficient to induce expression of the EI24 mRNA. The EI24 mRNA was also induced in a p53-dependent manner by ionizing irradiation of primary murine thymocytes. The invention is thus directed to an isolated EI24 protein, nucleotide sequences coding for and regulating expression of the protein, antibodies directed against the protein, and recombinant vectors and host cells containing the genetic sequences coding for and regulating the expression of the protein sequence. The invention is also directed to genomic DNA, cDNA, and RNA encoding the EI24 protein sequence and to corresponding antisense RNA sequences. Antibodies can be used to detect EI24 in biological specimens, including, for example, human tissue samples.

US Patent:

61909092, Feb 20, 2001

Filed:

Jun 25, 1997

Appl. No.:

8/884077

Inventors:

Doug Levinson - Sherborn MA
Wei Gu - Brookline MA
Sophie Lehar - Boston MA

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07H 2104
C12N 1512
C12N 1585

US Classification:

435325

Abstract:

The present invention relates to the discovery, identification and characterization of nucleic acids that encode a novel protein differentially expressed within the TH2 cell subpopulation (hereinafter referred to as STIF). The invention encompasses STIF nucleotides, host cell expression systems, STIF proteins, fusion proteins, polypeptides and peptides, antibodies to the STIF protein, transgenic animals that express a STIF transgene, or recombinant knock-out animals that do not express the STIF protein, and compounds that modulate STIF gene expression or STIF activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or used to treat STIF based disorders, such as proliferative disorders and T-lymphocyte-related disorders including, but not limited to, chronic inflammatory diseases and disorders, such as Crohn's disease, reactive arthritis, including Lyme disease, insulin-dependent diabetes, organ-specific autoimmunity, including multiple sclerosis, Hashimoto's thyroiditis and Grave's disease, contact dermatitis, psoriasis, graft rejection, graft versus host disease, sarcoidosis, atopic conditions, such as asthma and allergy, including allergic rhinitis, gastrointestinal allergies, including food allergies, eosinophilia, conjunctivitis, glomerular nephritis, certain pathogen susceptibilities such as helminthic (e. g. , leishmaniasis) and certain viral infections, including HIV, and bacterial infections, including tuberculosis and lepromatous leprosy.